Viewing Study NCT02296203


Ignite Creation Date: 2025-12-24 @ 7:16 PM
Ignite Modification Date: 2026-01-04 @ 3:48 PM
Study NCT ID: NCT02296203
Status: UNKNOWN
Last Update Posted: 2018-02-15
First Post: 2014-10-15
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).
Sponsor: Gruppo Oncologico del Nord-Ovest
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module